The Latest News July 30, 2020 argenx reports half year 2020 financial results and provides second quarter business update Breda, the Netherlands / Ghent, Belgium argenx today announced its half year 2020 financial results and provided a second quarter business update and outlook for the remainder of the year. View the webcast here. Read argenx More Press Releases News September 18, 2020 argenx to Present Additional Data from Global Phase 3 ADAPT Trial of Efgartigimod for Myasthenia Gravis at Upcoming Virtual Medical Meetings argenx today announced that it will present new data from the pivotal Phase 3 ADAPT trial at the Myasthenia Gravis Foundation of America (MGFA) 2020 Virtual Scientific Session. Read News September 2, 2020 argenx Management to Present at Upcoming Virtual Investor Conferences argenx today announced that members of management will participate in several upcoming conferences. Read News August 4, 2020 argenx to Present at 2020 Wedbush PacGrow Healthcare Virtual Conference argenx today announced that Tim Van Hauwermeiren, Chief Executive Officer, will present at the 2020 Wedbush PacGrow Healthcare Virtual Conference on Tuesday, August 11, 2020 at 12:35 p.m. ET. Read Media Center Publications ARGX-118 CIDP Cusatuzumab Efgartigimod Immune Thrombocytopenia Myasthenia Gravis Pemphigus Vulgaris SIMPLE Antibody Platform Facet Tags May 1, 2020 Making Asthma Crystal Clear April 16, 2020 Monoclonal antibodies against GARP/TGF-b1 complexes inhibit the immunosuppressive activity of human regulatory T cells in vivo April 13, 2020 ARGX-116 / A human APOC3 missense variant and monoclonal antibody accelerate apoC-III clearance and lower triglyceride-rich lipoprotein levels April 8, 2020 Protein crystallization promotes type 2 immunity and is reversible by antibody treatment April 7, 2020 SIMPLE Antibody platform / Dual anti-idiotypic purification of a novel, native-format biparatopic anti-MET antibody with improved in vitro and in vivo efficacy Load more
News September 18, 2020 argenx to Present Additional Data from Global Phase 3 ADAPT Trial of Efgartigimod for Myasthenia Gravis at Upcoming Virtual Medical Meetings argenx today announced that it will present new data from the pivotal Phase 3 ADAPT trial at the Myasthenia Gravis Foundation of America (MGFA) 2020 Virtual Scientific Session. Read
News September 2, 2020 argenx Management to Present at Upcoming Virtual Investor Conferences argenx today announced that members of management will participate in several upcoming conferences. Read
News August 4, 2020 argenx to Present at 2020 Wedbush PacGrow Healthcare Virtual Conference argenx today announced that Tim Van Hauwermeiren, Chief Executive Officer, will present at the 2020 Wedbush PacGrow Healthcare Virtual Conference on Tuesday, August 11, 2020 at 12:35 p.m. ET. Read
